![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ANKRD16 |
Gene summary for ANKRD16 |
![]() |
Gene information | Species | Human | Gene symbol | ANKRD16 | Gene ID | 54522 |
Gene name | ankyrin repeat domain 16 | |
Gene Alias | ANKRD16 | |
Cytomap | 10p15.1 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q6P6B7 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
54522 | ANKRD16 | HCC1_Meng | Human | Liver | HCC | 1.50e-46 | 8.74e-02 | 0.0246 |
54522 | ANKRD16 | HCC2_Meng | Human | Liver | HCC | 2.25e-05 | 6.39e-04 | 0.0107 |
54522 | ANKRD16 | HCC1 | Human | Liver | HCC | 1.70e-10 | 2.65e+00 | 0.5336 |
54522 | ANKRD16 | HCC2 | Human | Liver | HCC | 1.55e-27 | 3.07e+00 | 0.5341 |
54522 | ANKRD16 | HCC5 | Human | Liver | HCC | 5.82e-23 | 1.66e+00 | 0.4932 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00344702 | Liver | HCC | ncRNA processing | 293/7958 | 395/18723 | 4.26e-38 | 6.76e-35 | 293 |
GO:00346601 | Liver | HCC | ncRNA metabolic process | 332/7958 | 485/18723 | 1.48e-31 | 7.80e-29 | 332 |
GO:0008033 | Liver | HCC | tRNA processing | 87/7958 | 127/18723 | 2.66e-09 | 7.23e-08 | 87 |
GO:0006399 | Liver | HCC | tRNA metabolic process | 108/7958 | 179/18723 | 1.07e-06 | 1.59e-05 | 108 |
GO:0009451 | Liver | HCC | RNA modification | 101/7958 | 167/18723 | 2.02e-06 | 2.78e-05 | 101 |
GO:0006400 | Liver | HCC | tRNA modification | 60/7958 | 90/18723 | 3.09e-06 | 4.09e-05 | 60 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ANKRD16 | SNV | Missense_Mutation | rs774142230 | c.319N>T | p.Pro107Ser | p.P107S | Q6P6B7 | protein_coding | deleterious(0.04) | possibly_damaging(0.888) | TCGA-AN-A0XV-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
ANKRD16 | SNV | Missense_Mutation | rs764321371 | c.806N>A | p.Arg269Lys | p.R269K | Q6P6B7 | protein_coding | tolerated(0.21) | benign(0.023) | TCGA-WL-A834-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
ANKRD16 | SNV | Missense_Mutation | rs774503557 | c.725N>T | p.Ala242Val | p.A242V | Q6P6B7 | protein_coding | tolerated(0.06) | benign(0.294) | TCGA-A6-2681-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
ANKRD16 | SNV | Missense_Mutation | c.719N>T | p.Ala240Val | p.A240V | Q6P6B7 | protein_coding | tolerated(0.09) | possibly_damaging(0.548) | TCGA-AA-3864-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
ANKRD16 | SNV | Missense_Mutation | c.283G>A | p.Ala95Thr | p.A95T | Q6P6B7 | protein_coding | deleterious(0.01) | possibly_damaging(0.566) | TCGA-CM-4743-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Chemotherapy | capecitabine | SD | |
ANKRD16 | SNV | Missense_Mutation | novel | c.503N>T | p.Ser168Ile | p.S168I | Q6P6B7 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ANKRD16 | SNV | Missense_Mutation | rs368461065 | c.616N>A | p.Val206Ile | p.V206I | Q6P6B7 | protein_coding | tolerated(0.17) | benign(0.041) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
ANKRD16 | SNV | Missense_Mutation | rs140831926 | c.634N>A | p.Ala212Thr | p.A212T | Q6P6B7 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-A5-A0GM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ANKRD16 | SNV | Missense_Mutation | novel | c.1001C>A | p.Ser334Tyr | p.S334Y | Q6P6B7 | protein_coding | tolerated(0.11) | possibly_damaging(0.883) | TCGA-AX-A06F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
ANKRD16 | SNV | Missense_Mutation | novel | c.710N>C | p.Ser237Thr | p.S237T | Q6P6B7 | protein_coding | tolerated(0.48) | benign(0.001) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |